Dataset Information

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

ABSTRACT: ABSTACT:BACKGROUND: Many men diagnosed with prostate cancer are active surveillance (AS) candidates. However, AS may be associated with increased risk of disease progression and metastasis due to delayed therapy. Genomic classifiers, e.g., Decipher, may allow better risk-stratify newly diagnosed prostate cancers for AS. METHODS:Decipher was initially assessed in a prospective cohort of prostatectomies to explore the correlation with clinically meaningful biologic characteristics and then assessed in diagnostic biopsies from a retrospective multicenter cohort of 266 men with National Comprehensive Cancer Network (NCCN) very low/low and favorable-intermediate risk prostate cancer. Decipher and Cancer of the Prostate Risk Assessment (CAPRA) were compared as predictors of adverse pathology (AP) for which there is universal agreement that patients with long life-expectancy are not suitable candidates for AS (primary pattern 4 or 5, advanced local stage [pT3b or greater] or lymph node involvement). RESULTS:Decipher from prostatectomies was significantly associated with adverse pathologic features (p-values?

SUBMITTER: Kim HL

PROVIDER: S-EPMC6760567 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Kim Hyung L HL Li Ping P Huang Huei-Chung HC Deheshi Samineh S Marti Tara T Knudsen Beatrice B Abou-Ouf Hatem H Alam Ridwan R Lotan Tamara L TL Lam Lucia L C LLC du Plessis Marguerite M Davicioni Elai E Fleshner Neil N Lane Brian R BR Ross Ashley E AE Davis John W JW Mohler James L JL Trock Bruce J BJ Klein Eric A EA Tosoian Jeffrey J JJ Hyndman M Eric ME Bismar Tarek A TA

Prostate cancer and prostatic diseases 20181212 3

<h4>Abstact</h4>BACKGROUND: Many men diagnosed with prostate cancer are active surveillance (AS) candidates. However, AS may be associated with increased risk of disease progression and metastasis due to delayed therapy. Genomic classifiers, e.g., Decipher, may allow better risk-stratify newly diagnosed prostate cancers for AS.<h4>Methods</h4>Decipher was initially assessed in a prospective cohort of prostatectomies to explore the correlation with clinically meaningful biologic characteristics a ...[more]

PMID: 30542054

Similar Datasets

Project description:PurposeTo determine whether multiparametric magnetic resonance (MR) imaging can help identify patients with prostate cancer who would most appropriately be candidates for active surveillance (AS) according to current guidelines and to compare the results with those of conventional clinical assessment scoring systems, including the D'Amico, Epstein, and Cancer of the Prostate Risk Assessment (CAPRA) systems, on the basis of findings at prostatectomy.Materials and methodsThis institutional review board-approved HIPAA-compliant retrospectively designed study included 133 patients (mean age, 59.3 years) with a mean prostate-specific antigen level of 6.73 ng/mL (median, 4.39 ng/mL) who underwent multiparametric MR imaging at 3.0 T before radical prostatectomy. Informed consent was obtained from all patients. Patients were then retrospectively classified as to whether they would have met AS eligibility criteria or were better served by surgery. AS eligibility criteria for prostatectomy specimens were a dominant tumor smaller than 0.5 mL without Gleason 4 or 5 patterns or extracapsular or seminal vesicle invasion. Conventional clinical assessment scores (the D'Amico, Epstein, and CAPRA scoring systems) were compared with multiparametric MR imaging findings for predicting AS candidates. The level of significance of difference between scoring systems was determined by using the χ(2) test for categoric variables with the level of significance set at P < .05.ResultsAmong 133 patients, 14 were eligible for AS on the basis of prostatectomy results. The sensitivity, positive predictive value (PPV), and overall accuracy, respectively, were 93%, 25%, and 70% for the D'Amico system, 64%, 45%, and 88% for the Epstein criteria, and 93%, 20%, and 59% for the CAPRA scoring system for predicting AS candidates (P < .005 for all, χ(2) test), while multiparametric MR imaging had a sensitivity of 93%, a PPV of 57%, and an overall accuracy of 92% (P < .005).ConclusionMultiparametric MR imaging provides useful additional information to existing clinicopathologic scoring systems of prostate cancer and improves the assignment of treatment (eg, AS or active treatment).

Dataset Information

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Publications

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets